ARTMS Products and Telix Pharmaceuticals have signed a partnership covering the manufacturing of a radiopharmaceutical-based imaging agent based on the gallium-68 isotope.
Calling their technology molecularly targeted radiation (MTR), the firms agreed to use the Quantm gallium-68 production system from ARTMS in the manufacture of Telix's prostate cancer imaging agent TLX591-CDx for PET imaging.
ARTMS' cyclotron technology will be used to produce high-activity gallium-68, which will then be validated for use with Telix's production process for TLX591-CDx. ARTMS also will provide Telix with technical personnel to assist with solid-target irradiation of zinc-68, and it will utilize the company's intellectual property for high-activity processing of gallium-68.
